What is the current Haemato market capitalization?
The current market capitalization of Haemato is 89.94 M EUR.
Haemato Market capitalization 2024
Haemato Market capitalization
89.94 M EUR
Haemato Dividend yield
6.4 %
Ticker
HAEK.HM
ISIN
DE000A289VV1
WKN
A289VV
In 2024, Haemato's market cap stood at 89.94 M EUR, a -22.24% increase from the 115.67 M EUR market cap in the previous year.
The Haemato Market capitalization history
| YEAR | REVENUE (undefined EUR) | GROSS MARGIN (%) | NET INCOME (undefined EUR) |
|---|---|---|---|
| 2029e | 375.4 | 5,76 | - |
| 2028e | 357.07 | 6,05 | - |
| 2027e | 337.6 | 6,40 | - |
| 2026e | 316.08 | 6,84 | - |
| 2025e | 308.63 | 7,00 | 11.26 |
| 2024e | 286.72 | 7,54 | 10.21 |
| 2023e | 275.13 | 7,85 | 7.98 |
| 2022 | 248.14 | 8,71 | 8.19 |
| 2021 | 285 | 10,77 | 6.5 |
| 2020 | 238.3 | 7,43 | -4.8 |
| 2019 | 197.8 | 6,88 | -1.2 |
| 2018 | 274.1 | 7,70 | 6.3 |
| 2017 | 289.4 | 6,88 | 7 |
| 2016 | 275.6 | 7,08 | 11 |
| 2015 | 229.7 | 6,66 | 5.5 |
| 2014 | 202.7 | 8,04 | 7 |
| 2013 | 173.6 | 6,74 | 7.9 |
| 2012 | 25 | 28,40 | 6.8 |
| 2011 | 10.9 | 25,69 | 1.5 |
| 2010 | 23.7 | 3,38 | 5.7 |
| 2009 | 4.1 | -2,44 | -5.7 |
| 2008 | 13.8 | 42,75 | 4 |
| 2007 | 43.1 | 12,53 | 2.8 |
| 2006 | 28.5 | 38,95 | 8 |
| 2005 | 7 | 68,57 | 1.6 |
| 2004 | 11.6 | 29,31 | 2.9 |
| 2003 | - | - | - |
Haemato Aktienanalyse
What does Haemato do?
Haemato AG is a German company specializing in the trade of high-quality pharmaceuticals and medical products. It was founded in 1993 and has become one of the leading companies in this field. The company's goal is to offer quality medications and medical products for the German market. They carefully select products and collaborate with renowned manufacturers and suppliers to ensure success. Haemato AG is divided into different divisions specializing in the trade of various pharmaceuticals and medical products for oncology, pain therapy, rheumatology, and dermatology. They collaborate with Pfizer, Roche, and Merck for oncology medications. For pain therapy, they offer a range of products including pain relievers and specialized therapies. In rheumatology, they focus on diseases of the musculoskeletal system such as osteoporosis and arthritis. They provide a wide range of medications and medical products tailored to these diseases. In dermatology, they specialize in treating skin conditions such as psoriasis and eczema, offering a variety of medications and medical products. They also offer other products including medical devices like injection needles, syringes, EKG machines, and ultrasound devices. Their business model is based on close collaboration with leading manufacturers and suppliers to ensure high-quality products. They also prioritize comprehensive consultation and support for their customers to ensure they receive the right products for their specific needs. In summary, Haemato AG is a leading company in the pharmaceutical and medical product trade, offering a wide range of products and collaborating with top manufacturers and suppliers to provide high-quality and comprehensive solutions for medical needs. Haemato ist eines der beliebtesten Unternehmen auf Eulerpool.com.Market capitalization Details
Exploring Haemato's Market Capitalization
Haemato's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.
Year-to-Year Comparison
A yearly comparison of Haemato's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.
Impact on Investments
Haemato's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.
Interpreting Market Capitalization Fluctuations
Variations in Haemato’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.
Frequently Asked Questions about Haemato Stock
What is market capitalization?
The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Haemato.
How has the market capitalization of Haemato developed in recent years?
The market capitalization of Haemato has increased/decreased by -22.24% compared to the previous year.
What does market capitalization mean for investors?
The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.
Why is market capitalization an important indicator for investors?
The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.
Why does the market capitalization fluctuate?
The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.
What role does market capitalization play in the valuation of Haemato?
In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.
Does the market capitalization influence the performance of Haemato?
There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
Does the market capitalization of Haemato have an influence on indices?
Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).
How much dividend does Haemato pay?
Over the past 12 months, Haemato paid a dividend of 1.1 EUR . This corresponds to a dividend yield of about 6.4 %. For the coming 12 months, Haemato is expected to pay a dividend of 1.12 EUR.
What is the dividend yield of Haemato?
The current dividend yield of Haemato is 6.4 %.
When does Haemato pay dividends?
Haemato pays a quarterly dividend. This is distributed in the months of August, August, August, August.
How secure is the dividend of Haemato?
Haemato paid dividends every year for the past 0 years.
What is the dividend of Haemato?
For the upcoming 12 months, dividends amounting to 1.12 EUR are expected. This corresponds to a dividend yield of 6.49 %.
In which sector is Haemato located?
Haemato is assigned to the 'Health' sector.
Wann musste ich die Aktien von Haemato kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Haemato from 7/21/2023 amounting to 1.2 EUR, you needed to have the stock in your portfolio before the ex-date on 7/19/2023.
When did Haemato pay the last dividend?
The last dividend was paid out on 7/21/2023.
What was the dividend of Haemato in the year 2023?
In the year 2023, Haemato distributed 1.1 EUR as dividends.
In which currency does Haemato pay out the dividend?
The dividends of Haemato are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Haemato
Our stock analysis for Haemato Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Haemato Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.